Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Core Insights - Assembly Biosciences, Inc. reported significant progress in its clinical pipeline, particularly with positive interim results for its long-acting helicase-primase inhibitor candidate ABI-5366 in recurrent genital herpes [1][3] - The company raised $175 million in gross proceeds from equity financing, enhancing its financial position to support ongoing and future clinical developments [1][13] Herpes Simplex Virus (HSV) Developments - Positive Phase 1b interim results for ABI-5366 showed significant reductions in viral shedding and genital lesion rates in participants with recurrent genital herpes [1][7] - Enrollment in the Phase 1b study for ABI-5366 and two cohorts for ABI-1179 has been completed, with additional data expected by the end of the year [1][3][7] Hepatitis D Virus (HDV) Developments - Interim results from a Phase 1a study of ABI-6250, an oral HDV entry inhibitor, support progression to Phase 2 evaluation [1][7] - The pharmacokinetic profile of ABI-6250 indicates potential for once-daily dosing, with dose-dependent increases in a biomarker of target engagement [1][7] Financial Performance - Cash, cash equivalents, and marketable securities totaled $232.6 million as of September 30, 2025, compared to $75.0 million as of June 30, 2025, providing a cash runway into late 2027 [13] - Revenue from collaborative research with Gilead was $10.8 million for the three months ended September 30, 2025, an increase from $6.8 million in the same period in 2024 [13] - Research and development expenses rose to $16.6 million for the third quarter of 2025, up from $13.5 million in the same period in 2024, primarily due to increased spending on the HSV program [13]